Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
Influence of the Mismatched Minor Antigen HA-3 on Clear Graft Survival in Humans
Böhringer D.1, Reinhard T.2, Enczmann J.3, Spierings E.4, Goulmy E.4, Wernet P.3, Sundmacher R.1
1Eye hospital, 3Bone Marrow Donor centre and Institute for Transplantation Immunology, Heinrich-Heine-University, Düsseldorf; 2Eye Hospital, Albert-Ludwigs-University, Freiburg; 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden/NL
Purpose: Minor antigens (H) are HLA-restricted peptide-fragments of allelic cytosolic proteins. In animal-model keratoplasty, mismatched H-alleles presented within compatible HLA-molecules of the graft even exceed immunogenicity of mismatched HLA-molecules. Thus, in high-risk keratoplasty, where good HLA-compatibility is generally aimed at, additional matching of relevant H-loci is supposed to be beneficial. Immunogenic H-loci in human keratoplasty are currently undefined. HA-3 is an H-antigen that is presented within HLA-A1 and known to be expressed in human corneas. It can come as one of two alleles (T+/-): T+ is immunogenic to T-.
Method: HA-3 typing was performed retrospectively for 77 HLA-A1-compatible penetrating keratoplasties from deposited corneoscleral rims and peripheral blood cells, respectively. In both the immunogenic group (T+ graft for T- recipient) (n=8) and non-immunogenic controls (n=69) rejection-free clear graft survival was estimated